Alkemira
Company
Alkemira develops one asset, in phase 3 (Ketoprofen Topical Patch, 20% in osteoarthritis). Mostly small molecule acting on inflammation, PTGS2 and PTGS1.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Nonsteroidal anti-inflammatory drug inhibiting cyclooxygenase enzymes
Phase 3, Small molecule, Inflammation, PTGS2, osteoarthritis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6